BACKGROUND AND PURPOSE: Cisplatin drives specific types of tumour cells to apoptosis. In this study we investigate the involvement of intracellular calcium ([Ca(2+)](i)) in triggering apoptosis in two different cell lines. As cisplatin is used for the treatment of several forms of cancer we choose HeLa-S3 and U2-OS as two examples of tumour cell lines. EXPERIMENTAL APPROACH: Cisplatin (1 nM-10 microM) was applied to HeLa-S3 and U2-OS cells and [Ca(2+)](i) measured with fluo-4, using laser scanning microscopy. Inositol-1,4,5-trisphosphate (IP(3)) receptors were visualized with immunostaining. Membrane conductances were measured with patch-clamp techniques. Levels of calpain and caspases were assessed by western blots and apoptotic cells were stained with Hoechst 33342 and counted. KEY RESULTS: Cisplatin increases [Ca(2+)](i) concentration-dependently in HeLa-S3 but not in U2-OS cells. This elevation of [Ca(2+)](i) depended on extracellular Ca(2+) but was reduced by the IP(3) receptor blocker, 2-APB. This effect was not due to a Ca(2+) release triggered by Ca(2+) entry. Immunostaining showed IP(3)-receptors (type 1-3) at the cellular membrane of HeLa-S3 cells, but not in U2-OS cells. Electrophysiological experiments showed an increased membrane conductance with cisplatin only when Ca(2+) was present extracellularly. Increase of [Ca(2+)](i) was related to the activation of calpain but not caspase-8 and triggered apoptosis in HeLa-S3 but not in U2-OS cells. CONCLUSIONS AND IMPLICATIONS: Our observations on the activation of IP(3)-receptors, calcium entry and apoptotic rate by cisplatin in specific carcinogenic cells might open new possibilities in the treatment of some forms of cancer.
BACKGROUND AND PURPOSE:Cisplatin drives specific types of tumour cells to apoptosis. In this study we investigate the involvement of intracellular calcium ([Ca(2+)](i)) in triggering apoptosis in two different cell lines. As cisplatin is used for the treatment of several forms of cancer we choose HeLa-S3 and U2-OS as two examples of tumour cell lines. EXPERIMENTAL APPROACH: Cisplatin (1 nM-10 microM) was applied to HeLa-S3 and U2-OS cells and [Ca(2+)](i) measured with fluo-4, using laser scanning microscopy. Inositol-1,4,5-trisphosphate (IP(3)) receptors were visualized with immunostaining. Membrane conductances were measured with patch-clamp techniques. Levels of calpain and caspases were assessed by western blots and apoptotic cells were stained with Hoechst 33342 and counted. KEY RESULTS:Cisplatin increases [Ca(2+)](i) concentration-dependently in HeLa-S3 but not in U2-OS cells. This elevation of [Ca(2+)](i) depended on extracellular Ca(2+) but was reduced by the IP(3) receptor blocker, 2-APB. This effect was not due to a Ca(2+) release triggered by Ca(2+) entry. Immunostaining showed IP(3)-receptors (type 1-3) at the cellular membrane of HeLa-S3 cells, but not in U2-OS cells. Electrophysiological experiments showed an increased membrane conductance with cisplatin only when Ca(2+) was present extracellularly. Increase of [Ca(2+)](i) was related to the activation of calpain but not caspase-8 and triggered apoptosis in HeLa-S3 but not in U2-OS cells. CONCLUSIONS AND IMPLICATIONS: Our observations on the activation of IP(3)-receptors, calcium entry and apoptotic rate by cisplatin in specific carcinogenic cells might open new possibilities in the treatment of some forms of cancer.
Authors: Ana-Maria Florea; Frank Splettstoesser; Elke Dopp; Albert W Rettenmeier; Dietrich Büsselberg Journal: Toxicology Date: 2005-08-25 Impact factor: 4.221
Authors: Aleksandra Mandic; Kristina Viktorsson; Linda Strandberg; Thomas Heiden; Johan Hansson; Stig Linder; Maria C Shoshan Journal: Mol Cell Biol Date: 2002-05 Impact factor: 4.272
Authors: Michael Carland; Kristine J Tan; Jonathan M White; Jodie Stephenson; Vincent Murray; William A Denny; W David McFadyen Journal: J Inorg Biochem Date: 2005-08 Impact factor: 4.155
Authors: Yan Liu; Jian Yang; Hongmei Ren; Duofen He; Annabelle Pascua; M Ines Armando; Chengming Yang; Lin Zhou; Robin A Felder; Pedro A Jose; Chunyu Zeng Journal: Hypertens Res Date: 2009-08-07 Impact factor: 3.872
Authors: V Valiunas; G Kanaporis; L Valiuniene; C Gordon; H Z Wang; L Li; R B Robinson; M R Rosen; I S Cohen; P R Brink Journal: J Physiol Date: 2009-09-07 Impact factor: 5.182